Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Microsc ; 291(2): 145-155, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37155344

RESUMEN

Characterising the microstructure of foams is an important task for improving foam manufacturing processes and building foam numerical models. This study proposed a method for measuring the thickness of individual cell walls of closed-cell foams in micro-CT images. It comprises a distance transform on CT images to obtain thickness information of cell walls, a watershed transform on the distance matrix to locate the midlines of cell walls, identifying the intersections of midlines of cell walls by examining how many regions each pixel on the midlines of cell walls connects with, disconnecting and numbering the midlines of cell walls, extracting the distance values of the pixels on the midlines (or midplanes) of cell walls, and calculating the thickness of individual cell walls by multiplying the extracted distance values by two. Using this method, the thickness of cell walls of a polymeric closed-cell foam was measured. It was found that cell wall thickness measured in 2D images shows larger average values (around 1.5 times) and dispersion compared to that measured in volumetric images.


Asunto(s)
Polímeros , Microtomografía por Rayos X/métodos
2.
Nat Med ; 27(3): 480-490, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33723455

RESUMEN

Despite advances in technologies for cardiac repair after myocardial infarction (MI), new integrated therapeutic approaches still need to be developed. In this study, we designed a perfusable, multifunctional epicardial device (PerMed) consisting of a biodegradable elastic patch (BEP), permeable hierarchical microchannel networks (PHMs) and a system to enable delivery of therapeutic agents from a subcutaneously implanted pump. After its implantation into the epicardium, the BEP is designed to provide mechanical cues for ventricular remodeling, and the PHMs are designed to facilitate angiogenesis and allow for infiltration of reparative cells. In a rat model of MI, implantation of the PerMed improved ventricular function. When connected to a pump, the PerMed enabled targeted, sustained and stable release of platelet-derived growth factor-BB, amplifying the efficacy of cardiac repair as compared to the device without a pump. We also demonstrated the feasibility of minimally invasive surgical PerMed implantation in pigs, demonstrating its promise for clinical translation to treat heart disease.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos/instrumentación , Infarto del Miocardio/terapia , Prótesis e Implantes , Animales , Materiales Biocompatibles , Diseño de Equipo , Neovascularización Fisiológica , Porcinos , Remodelación Ventricular
3.
Biomed Res Int ; 2017: 8061091, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28232944

RESUMEN

Few studies have conducted follow-up investigations of the clinical course in HCV-related cirrhotic patients who achieved a sustained virological response (SVR) with pegylated interferon plus ribavirin treatment (PegIFN + RBV). We investigated the clinical course and laboratory data in a prospective cohort study enrolling HCV-related cirrhotic patients who received PegIFN + RBV between August 2008 and July 2013 in China. Complete blood counts, liver function tests, and HCV-RNA were serially examined. Liver-related complications were recorded. To detect hepatocellular carcinoma (HCC), alpha-fetoprotein assays, and ultrasound scans were repeated at 6-month intervals. Twenty-five patients were enrolled, including 8 patients with decompensation events before treatment. Eighteen patients achieved SVR with a mean follow-up period of 25.78 months. During the follow-up period, only one patient exhibited HCV-RNA positivity and no decompensation events were detected, but 4 patients developed HCC after SVR. APRI decreased more in patients with SVR than in patients with non-SVR (median, -1.33 versus 0.86, P < 0.001). The albumin levels and platelet counts significantly increased during the follow-up period after SVR (44.27 ± 4.09 versus 42.63 ± 4.37, P = 0.037 and 173.89 ± 87.36 versus 160.11 ± 77.97, P = 0.047). These data indicated that HCV-related cirrhotic patients with SVR after PegIFN + RBV may have a favorable clinical course and improvements in laboratory data. Moreover, HCC should be monitored.


Asunto(s)
Pueblo Asiatico , Hepacivirus/fisiología , Interferón-alfa/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/virología , Polietilenglicoles/química , Ribavirina/uso terapéutico , Adulto , Anciano , Alanina Transaminasa/sangre , Antivirales/uso terapéutico , Aspartato Aminotransferasas/sangre , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Hepacivirus/efectos de los fármacos , Humanos , Cirrosis Hepática/sangre , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Albúmina Sérica/metabolismo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA